Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.

ABSTRACT:

Background

Clinical guidelines have recommended annual follow-up examinations of most patients with monoclonal gammopathy of undetermined significance (MGUS); however, evidence supporting this practice is lacking. We performed a population-based study to examine the patterns of disease presentation and outcomes of patients with multiple myeloma, Waldenström macroglobulinemia, and lymphoplasmacytic lymphoma (monoclonal gammopathy-associated malignancies) comparing those with or without a previous MGUS follow-up examination.

Materials and methods

Patients with monoclonal gammopathy-associated malignancy from 1994 through 2007 were identified using the Surveillance, Epidemiology, and End Results-Medicare linked database and divided into 2 cohorts: those with follow-up (MGUS fol

SUBMITTER: Go RS 

PROVIDER: S-EPMC4344843 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature